Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Merck Sharp & Dohme (Australia) Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (115)
ARTG (99)
Prescription medicine registration (52)
Australian Public Assessment Report (AusPAR) (31)
Designation or determination (31)
Prescription medicine evaluation (9)
Prescription medicine decision summary (2)

Date

2024 (25)
2023 (33)
2022 (29)
2021 (31)
2020 (37)
2019 (52)
2018 (23)
2017 (3)
2016 (10)
2015 (6)
2014 (12)
2013 (16)
2012 (6)
2011 (4)
2009 (10)
2008 (6)
2007 (6)
2006 (10)
2005 (1)
2003 (1)
2002 (7)
2000 (1)
1998 (1)
1997 (5)
1996 (1)
1993 (1)
1991 (2)

Results for "[search-keyword]"

Search

Sponsor content

339 result(s) found, displaying 191 to 200

ASTROMIDE temozolomide 140 mg capsule sachet Cancelled under Section 30(1)(c) of the Act

28 June 2019

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
ASTROMIDE temozolomide 180 mg capsule sachet Cancelled under Section 30(1)(c) of the Act

28 June 2019

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
ASTROMIDE temozolomide 250mg capsule sachet Cancelled under Section 30(1)(c) of the Act

28 June 2019

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
ASTROMIDE temozolomide 100mg capsule bottle Cancelled under Section 30(1)(c) of the Act

28 June 2019

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
ASTROMIDE temozolomide 250mg capsule bottle Cancelled under Section 30(1)(c) of the Act

28 June 2019

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
ASTROMIDE temozolomide 140 mg capsules bottle Cancelled under Section 30(1)(c) of the Act

28 June 2019

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
ASTROMIDE temozolomide 180 mg capsules bottle Cancelled under Section 30(1)(c) of the Act

28 June 2019

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
PREGNYL gonadotrophin - chorionic human 1500IU powder for injection ampoule with diluent ampoule Cancelled under Section 30(1)(c) of the Act

27 June 2019

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
PREGNYL gonadotrophin - chorionic human 5000IU powder for injection ampoule with diluent ampoule Cancelled under Section 30(1)(c) of the Act

27 June 2019

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
Notice for pembrolizumab (Merck Sharp & Dohme (Australia) Pty Ltd)

5 June 2019

Designation or determination

Provisional approval

Pages

First page
Previous page
…
Page 16
Page 17
Page 18
Page 19
Current page 20
Page 21
Page 22
Page 23
Page 24
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.